This refers to a compound having the General formula (1), optionally in the form of a Salt, solvate, polymorphic, prodrug, cof u00e1rmaco, cocristal, taut u00f3mero, or pharmaceutically acceptable Diastere u00f3mero enantiomer of racemate, or mixtures thereof, which are useful in the Treatment To the improvement or prevention of a viral disease.In addition, specific Combination Treatments are reported.Claim 1: a compound having the General formula (1), optionally in the form of a pharmaceutically acceptable Salt, solvate, polymorphic, prodrug, cof u00e1rmaco, cocristal, taut u00f3mero enantiomer of racemate, or Diastere u00f3mero, or their mixtures, where x u00b9 u2070 is nr u00b9 u2075, N (r u00b9 u2075), C (C (o) Or nr u00b9 u2075), or C (o) C (o) or oC (n, o)； (r u00b9 u2075) SO u2082, so u2082n (r u00b9 u2075), S, so, or SO u2082； r u00b9 u2070 is HA c u2081 u208b u2086 alkyl group or a Group - C (o) - alkyl c u2081 u208b u2086； r u00b9 u00b9 is H, an alkyl group or alkyl group c u2081 u208b u2086, c u2081 u208b u2086 is replaced by one or more Halogen Atoms； r u00b9 u00b2 is H, an alkyl group c u2081 u208b u2086,Alkyl group or a c u2081 u208b u2086 is replaced by one or more Halogen Atoms； or where r u00b9 u00b9 and r u00b9 u00b2 can join each other to form a Ring or Heterocyclic Carbo 3 to 7 members； r u00b9 u00b3 is r u00b9 u2076 -, - or - x u00b9 u2070 r u00b9 u2076； r u00b9 u2074 is - H - (alkyl, optionally c u2081 u208b u2086 sust Ituido) - (optionally substituted cycloalkyl c u2083 u208b u2087) - (optionally substituted aryl)- c u2081 u208b u2084 - (alkyl or cycloalkyl, optionally substituted c u2083 u208b u2087) - alkyl - (optionally substituted aryl c u2081 u208b u2084)； r u00b9 u2075 is - H, - (alkyl, optionally substituted c u2081 u208b u2086) - (optionally substituted cycloalkyl c u2083 u208b u2087) - (optionally substituted aryl (alkyl) - c u2081 u208b u2084 - CLC Loalquilo c u2083 u208b u2087 optionally replaced)- c u2081 u208b u2084 - (aryl or alk
